Production approval for Orelabrutinib

Release date: 2024-07-10 14:01:21     Article From: Lucius Laos     Recommended: 95

05L0971_23 奥希替尼 批文_00.jpg

Suitable for adult mantle cell lymphoma (MCL) patients who have received at least one treatment in the past. Adult chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients who have received at least one treatment in the past. Used to treat patients with relapsed/refractory marginal zone lymphoma (MZL).

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.

Contact US

Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos

E-mail:laoslucius@gmail.com

Whatsapp:

ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved